These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9262275)

  • 1. The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilization treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries.
    Rimington MR; Walker SM; Shaw RW
    Hum Reprod; 1997 Jul; 12(7):1443-7. PubMed ID: 9262275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA; Barmat L; Liu HC; Davis OK; Rosenwaks Z
    Hum Reprod; 1997 Nov; 12(11):2359-65. PubMed ID: 9436663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Laparoscopic electrocoagulation of the ovaries prior to in vitro fertilization in two females with polycystic ovary syndrome].
    Brandsma I; Oosterhuis GJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(24):1350-2. PubMed ID: 16008040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on clinical effect on infertility women with polycystic ovary syndrome treated by in vitro maturation and in vitro fertilization-embryo transfer].
    Yu R; Lin J; Zhao JZ; Wang PY; Xiao SQ; Zhang W
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):250-4. PubMed ID: 22781109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.
    Chen CD; Wu MY; Yang JH; Chen SU; Ho HN; Yang YS
    Fertil Steril; 1997 Aug; 68(2):287-91. PubMed ID: 9240258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follicular aspiration during the selection phase prevents severe ovarian hyperstimulation in patients with polycystic ovary syndrome who are undergoing in vitro fertilization.
    Zhu WJ; Li XM; Chen XM; Zhang L
    Eur J Obstet Gynecol Reprod Biol; 2005 Sep; 122(1):79-84. PubMed ID: 16154042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coasting may reduce the severity of the ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome.
    Ohata Y; Harada T; Ito M; Yoshida S; Iwabe T; Terakawa N
    Gynecol Obstet Invest; 2000; 50(3):186-8. PubMed ID: 11014952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome.
    Aboulghar MA; Mansour RT; Serour GI; Amin YM; Sattar MA; elAttar E
    Fertil Steril; 1996 Nov; 66(5):757-60. PubMed ID: 8893680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Prolonged coasting': an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization.
    Sher G; Zouves C; Feinman M; Maassarani G
    Hum Reprod; 1995 Dec; 10(12):3107-9. PubMed ID: 8822423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study.
    Tan SL; Balen A; el Hussein E; Campbell S; Jacobs HS
    Fertil Steril; 1992 Aug; 58(2):378-83. PubMed ID: 1633906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
    Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
    Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro fertilization: a prospective randomized study.
    Egbase PE; Makhseed M; Al Sharhan M; Grudzinskas JG
    Hum Reprod; 1997 Dec; 12(12):2603-6. PubMed ID: 9455821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro fertilization following laparoscopic ovarian diathermy in patients with polycystic ovarian syndrome.
    Colacurci N; Zullo F; De Franciscis P; Mollo A; De Placido G
    Acta Obstet Gynecol Scand; 1997 Jul; 76(6):555-8. PubMed ID: 9246962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.